Drug Discovery Outsourcing Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Drug Discovery Outsourcing Market, By Workflow

7.1.  Drug Discovery Outsourcing Market, By Workflow Type, 2020-2030

7.1.1.    Target Identification & Screening

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Target Validation & Functional Informatics

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Lead Identification & Candidate Optimization

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Preclinical Development

7.1.4.1.        Market Revenue and Forecast (2016-2030)

7.1.5.    Other Associated Workflow

7.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Drug Discovery Outsourcing Market, By Therapeutics Area

8.1.  Drug Discovery Outsourcing Market, By Therapeutics Area, 2020-2030

8.1.1.    Respiratory System

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Pain & Anesthesia

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Oncology

8.1.3.1.        Market Revenue and Forecast (2016-2030)

8.1.4.    Ophthalmology

8.1.4.1.        Market Revenue and Forecast (2016-2030)

8.1.5.    Hematology

8.1.5.1.        Market Revenue and Forecast (2016-2030)

8.1.6.    Cardiovascular

8.1.6.1.        Market Revenue and Forecast (2016-2030)

8.1.7.    Immunomodulation

8.1.7.1.        Market Revenue and Forecast (2016-2030)

8.1.8.    Anti-Infective

8.1.8.1.        Market Revenue and Forecast (2016-2030)

8.1.9.    Central Nervous System

8.1.9.1.        Market Revenue and Forecast (2016-2030)

8.1.10.  Dermatology

8.1.10.1.      Market Revenue and Forecast (2016-2030)

8.1.11.  Genitourinary System

8.1.11.1.      Market Revenue and Forecast (2016-2030)

8.1.12.  Endocrine

8.1.12.1.      Market Revenue and Forecast (2016-2030)

8.1.13.  Gastrointestinal

8.1.13.1.      Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Drug Discovery Outsourcing Market, By Drug Type

9.1.  Drug Discovery Outsourcing Market, By Drug Type, 2020-2030

9.1.1.    Small Molecules

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Large Molecules (Biopharmaceuticals)

9.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, By Workflow (2016-2030)

10.1.2.  Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.1.3.  Market Revenue and Forecast, By Drug Type (2016-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.1.4.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.1.4.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.1.5.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.1.5.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, By Workflow (2016-2030)

10.2.2.  Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.2.3.  Market Revenue and Forecast, By Drug Type (2016-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.2.4.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.2.4.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.2.5.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.2.5.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.2.6.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.2.6.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.2.7.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.2.7.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, By Workflow (2016-2030)

10.3.2.  Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.3.3.  Market Revenue and Forecast, By Drug Type (2016-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.3.4.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.3.4.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.3.5.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.3.5.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.3.6.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.3.6.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.3.7.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.3.7.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, By Workflow (2016-2030)

10.4.2.  Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.4.3.  Market Revenue and Forecast, By Drug Type (2016-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.4.4.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.4.4.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.4.5.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.4.5.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.4.6.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.4.6.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.4.7.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.4.7.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, By Workflow (2016-2030)

10.5.2.  Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.5.3.  Market Revenue and Forecast, By Drug Type (2016-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.5.4.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.5.4.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, By Workflow (2016-2030)

10.5.5.2.      Market Revenue and Forecast, By Therapeutics Area (2016-2030)

10.5.5.3.      Market Revenue and Forecast, By Drug Type (2016-2030)

Chapter 11.  Company Profiles

11.1.              Albany Molecular Research Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              EVOTEC

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Laboratory Corporation of America Holdings

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              GenScript

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Pharmaceutical Product Development, LLC

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Charles River

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              WuXi AppTec

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Merck & Co., Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Thermo Fisher Scientific Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Dalton Pharma Services

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           Oncodesign

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

11.12.           Jubilant Biosys

11.12.1.               Company Overview

11.12.2.               Product Offerings

11.12.3.               Financial Performance

11.12.4.               Recent Initiatives

11.13.           DiscoverX Corporation

11.13.1.               Company Overview

11.13.2.               Product Offerings

11.13.3.               Financial Performance

11.13.4.               Recent Initiatives

11.14.           QIAGEN

11.14.1.               Company Overview

11.14.2.               Product Offerings

11.14.3.               Financial Performance

11.14.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms

Report Details

  • Report Code:37708
  • Category:Healthcare
  • No. of Pages:250
  • Format:PDF/PPT/Excel
  • Published:April 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers